161 related articles for article (PubMed ID: 38149471)
21. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel for platinum-refractory advanced thymic carcinoma.
Watanabe N; Umemura S; Niho S; Kirita K; Matsumoto S; Yoh K; Ohmatsu H; Goto K
Jpn J Clin Oncol; 2015 Jul; 45(7):665-9. PubMed ID: 25840444
[TBL] [Abstract][Full Text] [Related]
23. Metastatic thymic epithelial tumors: A regional cancer center experience.
Lakshmaiah KC; Chaudhuri T; Babu GK; Dasappa L; Jacob LA; Babu MCS; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2018; 55(3):288-291. PubMed ID: 30693896
[TBL] [Abstract][Full Text] [Related]
24. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial.
Loehrer PJ; Jiroutek M; Aisner S; Aisner J; Green M; Thomas CR; Livingston R; Johnson DH
Cancer; 2001 Jun; 91(11):2010-5. PubMed ID: 11391579
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy for thymic carcinoma and advanced thymoma in adults.
Wei ML; Kang D; Gu L; Qiu M; Zhengyin L; Mu Y
Cochrane Database Syst Rev; 2013 Aug; 2013(8):CD008588. PubMed ID: 23970462
[TBL] [Abstract][Full Text] [Related]
26. [Chemotherapy for thymic carcinoma].
Okuma Y
Gan To Kagaku Ryoho; 2012 May; 39(5):702-7. PubMed ID: 22584319
[TBL] [Abstract][Full Text] [Related]
27. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.
Sato J; Satouchi M; Itoh S; Okuma Y; Niho S; Mizugaki H; Murakami H; Fujisaka Y; Kozuki T; Nakamura K; Nagasaka Y; Kawasaki M; Yamada T; Machida R; Kuchiba A; Ohe Y; Yamamoto N
Lancet Oncol; 2020 Jun; 21(6):843-850. PubMed ID: 32502444
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy of thymic carcinoma: analysis of seven cases and review of the literature.
Kitami A; Suzuki T; Kamio Y; Suzuki S
Jpn J Clin Oncol; 2001 Dec; 31(12):601-4. PubMed ID: 11902491
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma.
Lemma GL; Lee JW; Aisner SC; Langer CJ; Tester WJ; Johnson DH; Loehrer PJ
J Clin Oncol; 2011 May; 29(15):2060-5. PubMed ID: 21502559
[TBL] [Abstract][Full Text] [Related]
30. Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma.
Agatsuma T; Koizumi T; Kanda S; Ito M; Urushihata K; Yamamoto H; Hanaoka M; Kubo K
J Thorac Oncol; 2011 Dec; 6(12):2130-4. PubMed ID: 21892103
[TBL] [Abstract][Full Text] [Related]
31. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab in combination with paclitaxel and platinum for previously treated advanced thymic epithelial tumors.
Wang CL; Gao LT; Lyu CX; Zhang Q; Zeng WQ; Fang WT; Zhu L; Fu XL
Med Oncol; 2022 Jan; 39(2):25. PubMed ID: 34982283
[TBL] [Abstract][Full Text] [Related]
33. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
[TBL] [Abstract][Full Text] [Related]
34. A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors.
Kim HS; Lee JY; Lim SH; Sun JM; Lee SH; Ahn JS; Park K; Moon SH; Ahn MJ
J Thorac Oncol; 2015 Dec; 10(12):1800-6. PubMed ID: 26484631
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.
Loehrer PJ; Chen M; Kim K; Aisner SC; Einhorn LH; Livingston R; Johnson D
J Clin Oncol; 1997 Sep; 15(9):3093-9. PubMed ID: 9294472
[TBL] [Abstract][Full Text] [Related]
36. Thymic epithelial neoplasms: a 12-year Canadian regional cancer program experience.
Wheatley-Price P; Jonker H; Jonker D; Shamji F; Gomes MM
Clin Lung Cancer; 2014 May; 15(3):231-6. PubMed ID: 24485232
[TBL] [Abstract][Full Text] [Related]
37. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L.
Hirai F; Yamanaka T; Taguchi K; Daga H; Ono A; Tanaka K; Kogure Y; Shimizu J; Kimura T; Fukuoka J; Iwamoto Y; Sasaki H; Takeda K; Seto T; Ichinose Y; Nakagawa K; Nakanishi Y;
Ann Oncol; 2015 Feb; 26(2):363-8. PubMed ID: 25403584
[TBL] [Abstract][Full Text] [Related]
38. Platinum-based chemotherapy with or without thoracic radiation therapy in patients with unresectable thymic carcinoma.
Nakamura Y; Kunitoh H; Kubota K; Sekine I; Shinkai T; Tamura T; Kodama T; Sumi M; Kohno S; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):385-8. PubMed ID: 11095135
[TBL] [Abstract][Full Text] [Related]
39. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
[TBL] [Abstract][Full Text] [Related]
40. RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.
Imbimbo M; Vitali M; Fabbri A; Ottaviano M; Pasello G; Petrini I; Palmieri G; Berardi R; Zucali P; Ganzinelli M; Marabese M; Broggini M; Marino M; Trama A; Rulli E; Hollander L; Pruneri G; Torri V; Garassino MC
Clin Lung Cancer; 2018 Sep; 19(5):e811-e814. PubMed ID: 30033090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
